

Genovis Expands License Agreement to Access Proprietary Enzyme Technology for Therapeutic Antibody-Drug Conjugate Development

Genovis AB, a leading provider of innovative enzyme technologies, today announced an expansion of its license agreement with Thermo Fisher Scientific to gain access to proprietary enzyme technology to develop and manufacture antibody-drug conjugates (ADCs) intended for therapeutic use. This broadens the scope of the original license agreement – previously limited to discovery and preclinical research – and represents a significant step forward to help enable innovative targeted cancer therapies.

Since the launch of its GlyCLICK® site-specific antibody labeling technology in 2017, Genovis has continuously expanded its offering within the antibody conjugation market. This has gained broad adoption across multiple areas of research, including antibody development, preclinical imaging, and ADCs. Particularly in recent years, the ADC market has experienced rapid growth, with pharmaceutical companies actively seeking new and improved technologies to attach payloads to antibodies in the creation of next-generation ADCs.

“We are excited to deepen our collaboration with Thermo Fisher Scientific,” said Fredrik Olsson, CEO at Genovis. “Expanding the license to therapeutic applications allows our technology to support the advancement of promising ADC candidates into clinical development and, ultimately, the market.”

With this expanded collaboration, Genovis is now well-positioned to support its customers across the entire ADC development pipeline—from early discovery to therapeutic manufacturing—unlocking new value in a high-growth market.


More about GlyCLICK®

GlyCLICK is based on a technology platform in which Genovis’ unique enzyme GlycINATOR is combined with SiteClick™ technology from Thermo Fisher Scientific. GlyCLICK is a platform for labeling antibodies at the same site (site specific) each time, with high reproducibility and with a broad range of applications. GlyCLICK can be used to label antibodies with markers for microscopy, preclinical imaging or to activate the antibody for labeling in chemotherapy. Labeling antibodies with various markers is a technique used in several areas of pharmaceutical research and development. Using the GlyCLICK technology platform, the label always attaches at precisely the same site and it is possible to label with many different markers, which makes the technology both versatile and scalable. For more information about GlyCLICK (www.genovis.com/glyclick).

Contacts

Fredrik Olsson, CEO

Tel: +46 (0)70-276 46 56 fredrik.olsson@genovis.com



Pressrelease July 24, 2025

About Us

Headquartered in Kävlinge, Sweden, Genovis offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis enzyme products, known as SmartEnzymes, are used by scientists all over the world and the innovative product formats facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and DNB Carnegie Investment Bank AB is the Company's Certified Adviser.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.